Current Report Filing (8-k)
September 17 2018 - 12:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 16, 2018
VBI VACCINES INC.
(Exact name of registrant as specified in its
charter)
British
Columbia, Canada
|
|
001-37769
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
|
|
02142
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
(617) 830-3031
(Registrant’s telephone number, including
area code)
N/A
(Former Name or former address, if changed since
last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
[X]
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item 8.01 Other Events.
On September 16, 2018,
VBI Vaccines Inc. issued a press release responding to allegations in an article published in Globes, Israel business news, on
September 12, 2018. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated
by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
VBI Vaccines Inc.
|
|
|
|
Date: September 17, 2018
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff Baxter
|
|
|
President and Chief Executive Officer
|
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Sep 2023 to Sep 2024